Effect of rimonabant on carotid intimaemedia thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: The AUDITOR Trial

Heart

Volumn 97, Issue 14, 2011, Pages 1143-1150

  O'Leary, Daniel H ^a   Reuwer, Anne Q ^b   Nissen, Steven E ^c   Després, Jean Pierre ^d   Deanfield, John E ^e   Brown, Michael W ^f   Zhou, Rong ^g   Zabbatino, Salvatore M ^f   Job, Bernard ^h   Kastelein, John J P ^b   Visseren, Frank L J ⁱ  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LERNER RESEARCH INSTITUTE   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Imagepace   (United States)

^g Medpace ^*  (United States)

^h SANOFI   (France)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIMONABANT;

ABDOMINAL OBESITY; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; MULTICENTER STUDY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUICIDAL IDEATION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; CANADA; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; PIPERIDINES; PLACEBO EFFECT; PROSPECTIVE STUDIES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA; TUNICA MEDIA; UNITED STATES; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 80955180984     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2011.223446     Document Type: Article

References (22)

1. Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAJ 2002;166:1039-40.
2. Wang Y, Mi J, Shan XY, et al. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007;31:177-88. (Pubitemid 46006032)
3. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004;53:2087-94. (Pubitemid 38970759)
4. Kaess BM, Jozwiak J, Mastej M, et al. Association between anthropometric obesity measures and coronary artery disease: a cross-sectional survey of 16,657 subjects from 444 Polish cities. Heart 2010;96:131-5.
5. Gruson E, Montaye M, Kee F, et al. Anthropometric assessment of abdominal obesity and coronary heart disease risk in men: the PRIME study. Heart 2010;96:136-40.
6. Wassink AM, van der Graaf Y, Olijhoek JK, et al; SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2008;29:213-23.
7. Wassink AM, van der Graaf Y, Soedamah-Muthu SS; Smart Study Group. Metabolic syndrome and incidence of type 2 diabetes in patients with manifest vascular disease. Diab Vasc Dis Res 2008;5:114-22. (Pubitemid 351839283)
8. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29:2959-71.
9. Nogueiras R, Diaz-Arteaga A, Lockie SH, et al. The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 2009;60:93-8.
10. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34. (Pubitemid 41653104)
11. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75. (Pubitemid 43244304)
12. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72. (Pubitemid 46048528)
13. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97. (Pubitemid 40523733)
14. Van Gaal LF, Scheen AJ, Rissanen AM, et al. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J 2008;29:1761-71. (Pubitemid 352019811)
15. Despres JP, Ross R, Boka G, et al. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-23.
16. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
17. Plantinga Y, Dogan S, Grobbee DE, et al. Carotid intima-media thickness measurement in cardiovascular screening programmes. Eur J Cardiovasc Prev Rehabil 2009;16:639-44.
18. Dijk JM, Van Der Graaf Y, Bots ML, et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J 2006;27:1971-8. (Pubitemid 44297372)
19. Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-60. (Pubitemid 351482794)
20. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010;376:517-23.
21. Chaubey S, Nitsch D, Altmann D, et al. Differing effect of modifiable cardiovascular risk factors on intima-media thickening and plaque formation at different sites of the arterial vasculature. Heart 2010;96:1579-85.
22. Franco OH, Massaro JM, Civil J, et al. Trajectories of entering the metabolic syndrome: the Framingham heart study. Circulation 2009;120:1943-50.